GlassScriptPhysician profile
Raisa A Mayers
NPI 1811555139
$4,006.86
in general payments reported to CMS, 2019-2025
28 companies · $2,619 in 2025
The $2,619 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.93 · 2022: $176 · 2023: $224 · 2024: $951 · 2025: $2,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,751 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,751.45 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $649.64 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $401.29 | 2024-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $381.82 | 2023-2025 | Korlym |
| Lilly USA, LLC | $257.24 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Alexion Pharmaceuticals, INC. | $239.78 | 2024-2025 | Strensiq |
| Beta Bionics, INC. | $239.01 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $214.47 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $202.06 | 2023-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $181.64 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $148.12 | 2025 | |
| Mannkind Corporation | $134.80 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 | |
| Radius Health, INC. | $116.07 | 2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $87.62 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.37 | 2024-2025 | Jardiance, Synjardy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $75.61 | 2025 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $73.00 | 2025 | Isturisa |
| Amneal Pharmaceuticals LLC | $68.43 | 2023-2025 | Unithroid |
| Abbott Laboratories | $66.13 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $55.15 | 2025 | Nexletol |
| Boston Scientific Corporation | $36.93 | 2019 | |
| Madrigal Pharmaceuticals | $31.13 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $30.68 | 2024-2025 | Contrave |
| Abbvie INC. | $25.99 | 2024 | |
| Sequel Med Tech, LLC | $25.62 | 2025 | Twiist |
| Averitas Pharma INC. | $19.36 | 2024 | Qutenza |
| Acella Pharmaceuticals, LLC | $19.30 | 2024 | NP Thyroid 60 |
| Ascendis Pharma Endocrinology INC | $15.60 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raisa Mayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.